PTPN1 Antibody

What is PTPN1/PTP1B and why is it important in research?

PTPN1 (Protein Tyrosine Phosphatase Non-receptor Type 1), also known as PTP1B, is a member of the protein tyrosine phosphatase superfamily. It functions as a regulator of endoplasmic reticulum unfolded protein response and plays crucial roles in various signaling pathways. As a ~50 kDa protein (435 amino acids), it consists of an N-terminal catalytic domain and a C-terminal regulatory segment that anchors it to the cytoplasmic face of the ER membrane . PTPN1 has emerged as an important research target due to its involvement in:

• Down-regulation of insulin and leptin signaling (therapeutic target for diabetes and obesity)

• Cancer progression and immune responses

• Regulation of EIF2AK3/PERK through dephosphorylation

• Modulation of CKII- and p60c-src-induced signal transduction cascades

• Regulation of EFNA5-EPHA3 signaling pathway affecting cell reorganization

• Hepatocyte growth factor receptor signaling pathway via MET dephosphorylation

What applications are PTPN1 antibodies commonly used for?

PTPN1 antibodies are utilized in multiple research applications with specific dilution recommendations:

It's essential to validate each antibody in your specific experimental system as performance may vary based on sample type and preparation methods .

What are the differences between monoclonal and polyclonal PTPN1 antibodies?

When selecting a PTPN1 antibody, understanding the differences between monoclonal and polyclonal options is crucial:

For applications requiring high specificity, such as distinguishing between PTPN1 and closely related phosphatases like TCPTP, monoclonal antibodies are often preferred. For applications where protein may be denatured (like Western blot), polyclonal antibodies might provide better detection .

How should I optimize PTPN1 antibody use for immunohistochemistry?

For optimal IHC results with PTPN1 antibodies, consider the following methodological approach:

• Antigen retrieval optimization:

  • For paraffin-embedded tissues, HIER (Heat-Induced Epitope Retrieval) at pH 6.0 (citrate buffer) or pH 9.0 (TE buffer) is recommended

  • Based on multiple sources, pH 9.0 often yields better results for PTPN1 detection

• Antibody dilution:

  • Begin with manufacturer's recommended range (typically 1:20-1:500)

  • Perform titration experiments using 2-fold serial dilutions

  • Optimal signal-to-noise typically shows specific cytoplasmic/perinuclear staining in target cells

• Positive control selection:

  • Human placenta (strong cytoplasmic positivity in trophoblastic cells)

  • Human breast cancer tissue (cytoplasmic/perinuclear localization)

  • Human prostate cancer tissue

• Detection system considerations:

  • HRP-DAB systems work well for PTPN1 visualization

  • Counterstaining with hematoxylin allows visualization of tissue architecture

• Scoring methodology:
  For semi-quantitative analysis, implement a composite scoring system:

  • Percentage scoring: 0 (negative), 1 (≤10%), 2 (11-50%), 3 (51-75%), 4 (>75%)

  • Intensity scoring: 1 (weak), 2 (moderate), 3 (strong)

  • Final score = Percentage × Intensity

Example: In breast cancer studies, this scoring approach successfully demonstrated correlation between PTPN1 expression and immune markers .

What are the key considerations for using PTPN1 antibodies in western blotting?

When using PTPN1 antibodies for western blotting, consider these methodological approaches:

• Sample preparation:

  • Cell lines validated for detection: THP-1, Jurkat, HeLa, A431, U-2 OS, Sp2/0, C6, NIH/3T3

  • Tissue samples: human placenta, mouse/rat liver, mouse placenta

  • Optimal lysis buffer: RIPA buffer with protease and phosphatase inhibitors

• Loading and transfer considerations:

  • Expected molecular weight: 45-55 kDa

  • Recommended loading: 10-30 μg total protein

  • Reduction conditions required (use DTT or β-mercaptoethanol)

  • Transfer conditions: wet transfer often yields better results than semi-dry

• Antibody selection and dilution:

  • Primary antibody dilution: 0.04-0.4 μg/ml or 1:2000-1:10000 dilution

  • Validated primary antibodies:

    • Rabbit polyclonal: 11334-1-AP (Proteintech), works at 1:2000-1:10000

    • Rabbit monoclonal: EPR22468-6 (Abcam), works at 1:1000

  • Secondary antibody: Anti-species HRP-conjugated at 1:5000-1:10000

• Blocking and washing optimization:

  • Optimal blocking: 5% non-fat milk in TBST (20 minutes at room temperature)

  • Alternative blocking: 3-5% BSA in TBST (recommended for phospho-specific detection)

  • Washing: TBST, 3-5 times for 5 minutes each

• Detection considerations:

  • Enhanced chemiluminescence (ECL) detection works well

  • Exposure time: Start with 30 seconds, adjust as needed

How can I effectively use PTPN1 antibodies for co-localization studies?

For effective co-localization studies with PTPN1 antibodies in immunofluorescence applications:

• Sample preparation protocol:

  • Fixation: 4% paraformaldehyde (10-15 minutes at room temperature)

  • Permeabilization: 0.1-0.2% Triton X-100 (10 minutes)

  • Blocking: 5% normal serum from the species of secondary antibody

• Antibody combinations for co-localization:

  • PTPN1 + ER markers (PTPN1 localizes to the endoplasmic reticulum)

  • PTPN1 + immune cell markers (CD8, CD163, PD-L1)

  • PTPN1 + signaling pathway components (insulin receptor, MET)

• Multi-channel imaging considerations:

  • Primary antibody combinations must be from different host species

  • Secondary antibodies should have well-separated fluorescent spectra

  • Include single-stain controls to assess bleed-through

• Quantification approaches:

  • Pearson's correlation coefficient for co-localization quantification

  • Manders' overlap coefficient for partial co-localization

  • Object-based analysis for discrete structures

• Validated examples from literature:

  • Co-localization between PTPN1 and scFv45 following insulin stimulation or H₂O₂ treatment has been demonstrated in Cos1 cells

  • Co-localization of PTPN1 with immune markers (CD8, CD163, PD-L1) in breast cancer tissues

This approach has successfully demonstrated PTPN1 co-localization with PD-L1 in tumor tissues, revealing important functional relationships .

How do I troubleshoot non-specific binding with PTPN1 antibodies?

Non-specific binding is a common challenge with PTPN1 antibodies. Follow this methodological approach to troubleshoot:

• Identify pattern of non-specific binding:

  • Background throughout tissue/cells: likely blocking issue

  • Unexpected bands in Western blot: potential cross-reactivity

  • Nuclear staining when cytoplasmic expected: potential fixation issue

• Systematic optimization steps:

  • For Western blot non-specificity:

    • Increase antibody dilution (try 2-5× more dilute)

    • Try alternative blocking agents (switch between milk and BSA)

    • Increase washing duration/frequency (5× 5-minute washes)

    • Add 0.05-0.1% Tween-20 to antibody diluent

    • Consider using BSA-free antibody formulations like NBP1-87191

  • For IHC/ICC non-specificity:

    • Optimize antigen retrieval (try both pH 6.0 and pH 9.0)

    • Include protein block step after antigen retrieval

    • Use species-matched serum for blocking (5-10%)

    • Ensure secondary antibody is highly cross-adsorbed

    • Consider knockout/knockdown validation controls

• Controls to implement:

  • Negative controls: omit primary antibody

  • Isotype controls: use non-specific IgG from same species

  • Knockout/knockdown validation: NBP1-87191 has been validated by knockout/knockdown

  • Peptide competition: pre-incubate antibody with immunizing peptide

• PTPN1-specific considerations:

  • Potential cross-reactivity with related PTPs (especially TCPTP)

  • PTPN1 exists in oxidized/reduced forms that may affect recognition

  • For oxidation-state specific detection, consider conformation-sensor antibodies like scFv45

What strategies can help detect low expression levels of PTPN1?

For detecting low expression levels of PTPN1, implement these methodological approaches:

• Signal amplification methods:

  • For Western blot:

    • Use high-sensitivity ECL substrate systems

    • Consider biotin-streptavidin amplification

    • Increase protein loading (50-100 μg)

    • Concentrate samples via immunoprecipitation before loading

  • For immunohistochemistry/immunofluorescence:

    • Implement tyramide signal amplification (TSA)

    • Use polymeric detection systems (e.g., EnVision)

    • Extend primary antibody incubation (overnight at 4°C)

    • Consider using biotin-conjugated secondary + streptavidin-HRP

• Sample preparation optimization:

  • Enrich target protein via subcellular fractionation (PTPN1 is membrane-associated)

  • Optimize lysis conditions to ensure complete extraction

  • Avoid freeze-thaw cycles that may degrade protein

  • Use protease inhibitors during all preparation steps

• Antibody selection strategies:

  • For low abundance detection, polyclonal antibodies may offer better sensitivity

  • Consider using antibodies validated for the specific application

  • Use antibodies with demonstrated sensitivity in your species of interest

• Validated approaches from literature:

  • Immunoprecipitation followed by Western blot has successfully detected low levels of PTPN1

  • Immunofluorescence with signal enhancement detected PTPN1 in oxidized states

  • Recombinant monoclonal antibodies like EPR22468-6 have shown high sensitivity

How can I distinguish between PTPN1 and other closely related phosphatases?

Distinguishing PTPN1 from related phosphatases (particularly TCPTP) requires careful methodological considerations:

• Antibody selection criteria:

  • Choose antibodies raised against unique regions of PTPN1

  • Look for antibodies specifically validated for distinguishing between family members

  • Consider monoclonal antibodies targeting unique epitopes

  • Review cross-reactivity data in product documentation

  • Validated examples: scFv45 shows specificity for PTPN1-OX (oxidized form) and doesn't interact with TCPTP following insulin stimulation or H₂O₂ treatment

• Experimental validation approaches:

  • Knockout/knockdown controls:

    • Use PTPN1-knockout cells as negative controls

    • Compare with knockdown of related phosphatases

    • NBP1-87191 is documented as being validated by knockout/knockdown

  • Expression pattern analysis:

    • PTPN1: Predominantly ER-localized with perinuclear distribution

    • TCPTP: Nuclear and cytoplasmic distribution

    • Immunofluorescence co-localization can help distinguish patterns

• Application-specific considerations:

  • For Western blot:

    • Run side-by-side comparisons with recombinant standards

    • Use gradient gels to better separate similar molecular weights

    • Consider 2D-gel separation for isoform discrimination

  • For IHC/ICC:

    • Validate staining patterns in tissues with known expression profiles

    • Use parallel sections with antibodies against related phosphatases

    • Implement multiplexed staining to directly compare localization

• Functional validation methods:

  • Substrate specificity assays (PTPN1 has distinct substrate preferences)

  • Inhibitor response profiles (specific inhibitors affect PTPN1 differently)

  • Response to oxidation (PTPN1-OX has unique conformational properties)

How can PTPN1 antibodies be used to investigate cancer immunity?

Recent research has established PTPN1 as an important player in cancer immunity. Here's a methodological approach to investigate this connection:

• Multiplexed immunoprofiling strategy:

  • Panel design for cancer immune microenvironment:

    • PTPN1 + TAM markers (CD68, CD163)

    • PTPN1 + T cell markers (CD8, CD4)

    • PTPN1 + immune checkpoint proteins (PD-L1)

  • Implementation methods:

    • Serial section IHC with quantitative image analysis

    • Multiplex immunofluorescence for co-localization

    • Flow cytometry for immune cell subpopulations

• Correlation analysis workflow:
  Recent studies have shown significant correlations between PTPN1 expression and immune cell infiltration in multiple cancer types:

  Immune Cell Type	Correlation with PTPN1	Cancer Types Showing Correlation
  CD8+ T cells	Positive	Breast cancer, multiple others
  CD163+ M2 TAMs	Positive	Breast cancer
  PD-L1 expression	Positive	Breast cancer
  Immune score	Variable	Multiple cancer types
  Stromal score	Variable	Multiple cancer types

  These correlations provide a foundation for investigating PTPN1's role in immune regulation .

• Experimental manipulation approaches:

  • PTPN1 knockdown/knockout studies:

    • shRNA knockdown of PTPN1 in cancer cells (e.g., 4T1 breast cancer model)

    • Analysis of tumor growth and immune infiltration

    • Quantification of CD8+ T cells and CD163+ M2-like TAMs

    • Assessment of PD-L1 expression changes

  • Findings from published research:

    • PTPN1 knockdown inhibited breast cancer cell tumorigenesis in vivo

    • PTPN1 deletion significantly reduced CD163+ M2-like TAMs (p=0.005)

    • Tumor infiltration of CD8+ T cells was lower in PTPN1 knockdown tumors

    • PTPN1 expression correlated positively with PD-L1 protein expression

• Therapeutic implication analysis:

  • Analysis of PTPN1 expression in relation to immunotherapy response

  • Studies in immunotherapy cohorts (IMvigor210, GSE78220, GSE91061)

  • Investigation of synergy between PTPN1 targeting and checkpoint inhibition

  • Potential for improving CAR-T cell efficacy through PTPN1 targeting

What are the approaches for using conformation-sensing PTPN1 antibodies?

Conformation-sensing antibodies represent an advanced tool for studying PTPN1 biology, particularly its oxidation states. Here's a methodological approach:

• Understanding PTPN1 conformational states:

  • PTPN1 undergoes significant conformational changes when oxidized (PTP1B-OX)

  • This reversible oxidation regulates PTPN1 activity in response to ROS

  • The oxidized form is catalytically inactive and has distinct structural features

  • Conformation-sensor antibodies can specifically recognize and stabilize PTP1B-OX

• Methodological strategies for conformation-specific detection:

  • scFv development and application:

    • Single chain variable fragments (scFvs) have been developed from immunized chickens

    • Phage display libraries with different linker lengths optimize binding

    • Validated examples: scFv45 specifically recognizes PTP1B-OX

    • Validation includes immunoprecipitation and co-localization assays

  • Implementation in cellular systems:

    • Expression as intrabodies to stabilize oxidized PTPN1

    • Co-immunoprecipitation to assess oxidation state

    • Immunofluorescence to visualize oxidized PTPN1 localization

    • Functional consequences assessment (enhanced insulin signaling)

• Analytical framework for oxidation state monitoring:

  • Experimental induction of oxidation:

    • Insulin stimulation (physiological oxidation)

    • H₂O₂ treatment (experimental oxidation)

    • Verification by redox-specific methods

  • Readouts for functional consequences:

    • Enhanced tyrosyl phosphorylation of insulin receptor β-subunit

    • Increased phosphorylation of IRS-1

    • Elevated PKB/AKT phosphorylation

• Advanced applications:

  • Drug discovery: screening for compounds that stabilize inactive conformations

  • Biosensor development: monitoring cellular redox changes in real-time

  • Structure-guided antibody engineering: optimizing conformation specificity

How can PTPN1 antibodies be used to investigate drug sensitivity and therapeutic responses?

PTPN1 has emerged as a biomarker for drug sensitivity and therapeutic response. Here's a methodological approach to investigate these relationships:

• Correlation analysis between PTPN1 expression and drug sensitivity:

  • Data sources and mining approach:

    • NCI-60 cancer cell line panel

    • GDSC (Genomics of Drug Sensitivity in Cancer) database

    • CellMiner web application for integrative analysis

  • Statistical framework:

    • Spearman correlation between PTPN1 expression and drug sensitivity

    • Multi-variant analysis accounting for cancer type and molecular features

    • Identification of drug classes with significant correlations

• Experimental validation methodology:

  • In vitro assessment:

    • PTPN1 knockdown/overexpression in cancer cell lines

    • CCK-8 assay to examine drug sensitivity changes

    • Dose-response curves and IC50 determination

    • Example finding: PTPN1 deletion increased sensitivity of breast cancer cells to paclitaxel

  • In vivo validation approaches:

    • Xenograft models with PTPN1-modulated cells

    • Treatment with identified drugs (e.g., paclitaxel)

    • Tumor growth, apoptosis, and pathway activation assessment

    • Immunohistochemical validation using anti-PTPN1 antibodies

• PTPN1 in immunotherapy response prediction:

  • Patient cohort analysis:

    • IMvigor210 (298 urological cancer patients)

    • GSE78220 (27 melanoma patients)

    • GSE91061 (49 melanoma patients)

  • Analytical framework:

    • PTPN1 expression in responders vs. non-responders

    • Correlation with immune checkpoint gene expression

    • Multivariate models incorporating TMB and MSI status

    • Finding: PTPN1 serves as a biomarker for immunotherapy response

• Therapeutic targeting implications:

  • Dual PTPN2/PTPN1 inhibition strategy:

    • Development of inhibitors like ABBV-CLS-484

    • Enhancement of anti-tumor immunity

    • Synergy with PD-1 checkpoint blockade

    • Improved efficacy of CAR-T cell therapies

How should I quantify and analyze PTPN1 expression in tumor samples?

For rigorous quantification and analysis of PTPN1 expression in tumor samples, implement this methodological framework:

• IHC scoring system standardization:

  • Semi-quantitative scoring approach:

    • Percentage scoring (P): 0 (negative), 1 (≤10%), 2 (11-50%), 3 (51-75%), 4 (>75%)

    • Intensity scoring (I): 1 (weak), 2 (moderate), 3 (strong)

    • Final score calculation: S = P × I

    • This approach was successfully used in breast cancer studies

  • Digital image analysis alternative:

    • Whole slide scanning at standardized resolution

    • Algorithm-based detection of positive cells

    • Quantification of staining intensity (optical density)

    • Cellular compartment-specific analysis (cytoplasmic vs. nuclear)

• Correlation with clinicopathological parameters:

  • Statistical framework:

    • Chi-square or Fisher's exact test for categorical variables

    • Mann-Whitney U test for continuous variables

    • Kaplan-Meier analysis with log-rank test for survival outcomes

    • Cox proportional hazards model for multivariate analysis

  • Key parameters to assess:

    • Tumor grade and stage

    • Molecular subtypes (e.g., in breast cancer)

    • Immune subtypes (C1-C6 as defined in pan-cancer analysis)

    • Patient survival (OS, DSS) and response to therapy

• Integration with molecular and immune data:

  • Multi-omics approach:

    • Correlation with gene expression data

    • Association with tumor mutational burden (TMB)

    • Relationship with microsatellite instability (MSI)

    • Integration with immune cell infiltration metrics

  • Visualization and analysis tools:

    • Heatmaps for expression patterns across sample types

    • Radar charts for visualizing correlations across multiple parameters

    • TIMER and ESTIMATE algorithms for immune infiltration analysis

• Validation in independent cohorts:

  • Cross-platform validation:

    • TCGA pan-cancer datasets

    • Immune checkpoint inhibitor treatment cohorts

    • In-house tissue microarrays

    • Different antibody clones to confirm findings

How do I interpret PTPN1 data in the context of different cancer types and immune subtypes?

Interpreting PTPN1 data across cancer types and immune subtypes requires a nuanced analytical approach:

• Cancer type-specific expression patterns:
  Research has demonstrated that PTPN1 expression and its prognostic significance vary across cancer types:

  Cancer Type	PTPN1 Expression Pattern	Prognostic Association	Immune Correlation
  Breast cancer	Higher in tumor vs. normal	Associated with improved OS	Positive correlation with CD8+ T cells and CD163+ TAMs
  Pancreatic (PAAD)	Varies by subtype	Prognostic biomarker	Strong correlation with immune checkpoint genes
  Liver (LIHC)	Varies by subtype	Prognostic biomarker	Strong correlation with immune checkpoint genes
  Lung (LUAD)	Varies by immune subtype	Prognostic biomarker	Strong correlation with immune checkpoint genes
  Ovarian (OV)	Varies by subtype	Prognostic biomarker	Strong correlation with immune checkpoint genes
  Uveal melanoma (UVM)	Varies by subtype	Prognostic biomarker	Strong correlation with immune checkpoint genes

  This highlights the importance of cancer-specific interpretation of PTPN1 data .

• Immune subtype contextual analysis:

  • Framework for immune subtype classification:

    • C1: Wound healing

    • C2: IFN-gamma dominant

    • C3: Inflammatory

    • C4: Lymphocyte-depleted

    • C5: Immunologically quiet

    • C6: TGF-β dominant

  • PTPN1 expression patterns across immune subtypes:

    • Significant variation observed across immune subtypes in multiple cancers

    • Example: In breast cancer, highest in C4 (lymphocyte-depleted), followed by C2 (IFN-gamma dominant)

    • Significant associations found in BLCA, BRCA, HNSC, LGG, LUAD, LUSC, PRAD, TGCT, THCA, and UCEC

• Analytical approach for molecular subtype associations:

  • Significant associations between PTPN1 expression and molecular subtypes observed in:

    • ACC, BRCA, COAD, ESCA, HNSC, LGG, LUSC, OV, PRAD, READ, STAD, and UCEC

  • This requires integration of molecular classification data with PTPN1 expression analysis

• Interpretative framework for mechanistic insights:

  • PTPN1's role in T cell function: elevated in intratumoral CD8+ T cells, potentially inhibiting anti-tumor immunity

  • Association with macrophage polarization: significant positive correlation with macrophages in most cancer types

  • Relationship with immune checkpoint expression: strong correlations with immune checkpoint genes, particularly in specific cancer types

  • Potential therapeutic implications: targeting PTPN1 may improve T cell-mediated anti-tumor immunity and synergize with checkpoint inhibitors

What are the challenges in interpreting conflicting PTPN1 data across different cancer models?

Researchers often encounter conflicting data regarding PTPN1's role in cancer. Here's a methodological framework for addressing these contradictions:

• Systematic approach to conflicting findings:

  • Data categorization by cancer type and model system:

    • Cell line vs. primary tissue

    • Animal models vs. human samples

    • In vitro vs. in vivo findings

    • Different methodological approaches

  • Conflicting patterns observed in literature:

    • PTPN1 as tumor-promoting vs. tumor-suppressing

    • Different prognostic associations across cancer types

    • Varying roles in immune regulation

• Context-dependent interpretation framework:

  • Cancer type specificity:

    • In breast cancer: PTPN1 shows both tumor-promoting and tumor-suppressing roles

    • Example conflict: "PTPN1 is associated with significantly improved OS in breast cancer" vs. "PTPN1 protein level is dramatically increased in breast cancer tissues and promotes proliferation"

    • Resolution approach: Consider molecular subtypes (e.g., ErbB2-positive vs. TNBC)

  • Functional context dependency:

    • PTPN1's role may differ based on:

      • Presence of PD-L1 expression

      • Oxidation state of the protein

      • Cell type expressing PTPN1 (tumor cells vs. immune cells)

    • Example resolution: In TNBC, PD-L1 physically interacts with PTPN1, potentially explaining contextual differences

• Technical factors affecting data interpretation:

  • Antibody selection influence:

    • Different epitopes targeted by antibodies may detect distinct conformations or isoforms

    • Specificity limitations may lead to detection of related phosphatases

    • Solution: Use multiple validated antibodies targeting different epitopes

  • Expression analysis methods:

    • Transcriptomic vs. proteomic data may show discrepancies

    • Localization vs. total expression may provide different insights

    • Post-translational modifications may not be captured in expression data

    • Solution: Integrate multiple detection methods and functional validation

• Integrative resolution strategy:

  • Multi-level data integration:

    • Combine genomic, transcriptomic, and proteomic data

    • Incorporate post-translational modification information

    • Consider cellular context and microenvironment

  • Mechanistic validation:

    • Functional studies with specific pathway inhibitors

    • Genetic manipulation (knockout/knockdown/overexpression)

    • Protein-protein interaction studies

    • Pharmacological modulation with PTPN1/PTPN2 inhibitors